Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021
February 10 2021 - 8:04AM
Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on
therapeutics for acute care settings, (“Baudax Bio” or the
“Company”) today announced that it will report full year 2020
financial results on Tuesday, February 16, 2021. Baudax’s
management team will host a conference call and webcast at 8:00
a.m. ET on Tuesday, February 16, 2021 to discuss the financial
results and recent operational highlights.
To access the conference call please dial (866)
220-5595 (local) or (615) 622-8062 (international) at least 10
minutes prior to the start time and refer to conference ID 4354098.
A live audio webcast of the call will be available under “Events”
in the Investor section of the Company’s website,
https://www.baudaxbio.com/news-and-investors/events. An archived
webcast will be available on the Company’s website approximately
two hours after the event and will be available for 30 days.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on therapeutics for acute care settings. The launch of Baudax Bio’s
first commercial product ANJESO® began in June 2020 following its
approval by the U.S. Food and Drug Administration in February 2020.
ANJESO is a once daily IV NSAID with preferential Cox-2 activity,
which has successfully completed three Phase III clinical trials,
including two pivotal efficacy trials, a large double-blind Phase
III safety trial and other studies for the management of moderate
to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of
other pharmaceutical assets including two novel neuromuscular
blocking agents (NMBAs) and a proprietary chemical reversal agent
specific to these NMBAs which is currently in preclinical studies,
and intranasal dexmedetomidine which is being developed for
possible uses in pain or sedation. For more information, please
visit www.baudaxbio.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,”
“intend,” and “expect,” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of
publication on this internet site and are subject to a number of
risks, uncertainties, and other factors that could cause Baudax
Bio’s performance to differ materially from those expressed in, or
implied by, these forward-looking statements. These forward-looking
statements are subject to risks and uncertainties including, among
other things, the ongoing economic and social consequences of the
COVID-19 pandemic, including any adverse impact on the commercial
launch of ANJESO® or disruption in supply chain, Baudax Bio’s
ability to maintain regulatory approval for ANJESO, Baudax Bio’s
ability to successfully commercialize ANJESO; the acceptance of
ANJESO by the medical community, including physicians, patients,
health care providers and hospital formularies; Baudax Bio’s
ability and that of Baudax Bio’s third party manufacturers to
successfully scale-up our commercial manufacturing process for
ANJESO, Baudax Bio’s ability to produce commercial supply in
quantities and quality sufficient to satisfy market demand for
ANJESO, Baudax Bio’s ability to raise future financing for
continued product development, payment of milestones and ANJESO
commercialization, Baudax Bio’s ability to pay its debt and satisfy
conditions necessary to access future tranches of debt, Baudax
Bio’s ability to comply with the financial and other covenants
under its credit facility, Baudax Bio’s ability to manage costs and
execute on our operational and budget plans, the accuracy of Baudax
Bio’s estimates of the potential market for ANJESO, Baudax Bio’s
ability to achieve its financial goals; and Baudax Bio’s ability to
obtain, maintain and successfully enforce adequate patent and other
intellectual property protection. These forward-looking statements
should be considered together with the risks and uncertainties that
may affect our business and future results included in our filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are based on information currently
available to us, and we assume no obligation to update any
forward-looking statements except as required by applicable
law.
CONTACT:
Investor Relations Contact:Argot PartnersSam Martin / Claudia
Styslinger(212) 600-1902baudaxbio@argotpartners.com
Baudax Bio, Inc.Ryan D. Lake(484)
395-2436rlake@baudaxbio.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024